Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Autolus Therapeutics PLCAUTL-2.8363.101.14-1.49-82.20%-12.31%46.34$3.60$4.3492,156$2.49

Detail of Autolus Therapeutics PLC

 
CEO
Dr. Christian Martin Itin Ph.D.
Employees
463
Industry
Biotechnology
Sector
Healthcare
Market cap
$662M

Company details

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Revenue
Revenue (Rev)
$10.50M
Autolus Therapeutics PLC
AUTL • XNGS • US
$2.49
-4.14 (-62.44%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.88
Margin profit
0.00%
52 week low
$2.49
52 week high
$7.29
50-day simple moving average
$3.06
200-day simple moving average
$3.60
Percent held by insiders
18.09%
Percent held by institutions
77.33%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
AUTL -62.44%
eps change
AUTL 0.00%